ISIS 113715
- Generic Name
- ISIS 113715
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant
reductions in LDL-cholesterol.
- Indication
Investigated for use/treatment in diabetes mellitus type 2.
- Associated Conditions
- -
- Associated Therapies
- -
Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2009-08-28
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT00455598
- Locations
- 🇷🇴
Oradea Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases, Oradea, Romania
🇷🇺Limited Liability Company "Clinic of New Medical Technologies", Moscow, Russian Federation
🇷🇴Private Practice "Morosanu V. Magdalena", Galati, Romania
Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2007-10-17
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00365781
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment
- Conditions
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2008-02-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT00330330
- Locations
- 🇷🇺
Close Corporation "MEDSI", Moscow, Russian Federation
🇵🇱NZOZ Specjalistyczny Osrodek Internistyczno Diabetologiczny, Bialystok, Poland
🇵🇱Prywatna Praktyka Lekarska, Radom, Poland
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
- Conditions
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT00330200
- Locations
- 🇺🇸
Yale - New Haven Hospital, New Haven, Connecticut, United States
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
- Conditions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT00327626
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Western Galilee Medical Center - Nahariya, Nahariya, Israel
🇮🇱Soroka Medical Center, BeEr-Sheva, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.